Original Article

You have full text access to this OnlineOpen article

Amifostine does not prevent platinum-induced hearing loss associated with the treatment of children with hepatoblastoma†‡

A report of the Intergroup Hepatoblastoma Study P9645 as a part of the Children's Oncology Group

  1. Howard M. Katzenstein MD1,§,*,
  2. Kay W. Chang MD2,
  3. Mark Krailo PhD3,
  4. Zhengjia Chen PhD4,
  5. Milton J. Finegold MD5,
  6. Jon Rowland MD, PhD6,
  7. Marleta Reynolds MD7,
  8. Alberto Pappo MD5,
  9. Wendy B. London PhD8,
  10. Marcio Malogolowkin MD9

Article first published online: 7 OCT 2009

DOI: 10.1002/cncr.24667

Issue

Cancer

Cancer

Volume 115, Issue 24, pages 5828–5835, 15 December 2009

Additional Information

How to Cite

Katzenstein, H. M., Chang, K. W., Krailo, M., Chen, Z., Finegold, M. J., Rowland, J., Reynolds, M., Pappo, A., London, W. B. and Malogolowkin, M. (2009), Amifostine does not prevent platinum-induced hearing loss associated with the treatment of children with hepatoblastoma. Cancer, 115: 5828–5835. doi: 10.1002/cncr.24667

Author Information

  1. 1

    Department of Pediatrics, Aflac Cancer Center of Children's Healthcare of Atlanta and Emory University, Atlanta, Georgia

  2. 2

    Department of Otolaryngology, Lucile Packard Children's Hospital at Stanford, Palo Alto, California

  3. 3

    Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California

  4. 4

    Group Operations Center, Children's Oncology Group Statistics and Data Center, Arcadia, California

  5. 5

    Departments of Pathology and Hematology/Oncology, Texas Children' Cancer Center, Baylor College of Medicine, Houston, Texas

  6. 6

    Department of Pathology, Children's Hospital of Oakland, Oakland, California

  7. 7

    Department of Surgery, Northwestern University and Children's Memorial Hospital, Chicago, Illinois

  8. 8

    Department of Statistics, University of Florida, Children's Oncology Group Data Center, Gainesville, Florida

  9. 9

    Department of Pediatrics, Children's Hospital, Los Angeles, California

  1. §

    Fax: (626) 445-4334

*Children's Oncology Group, 440 East Huntington Drive, Suite 400, Arcadia, CA 91066

  1. †

    See editorial on pages 5623–6, this issue.

  2. ‡

    We are extremely grateful for the hard work and diligence of the clinical research associates of our member institutions for data collection and to the Children' Oncology Group Publications Office for editorial assistance.

Publication History

  1. Issue published online: 2 DEC 2009
  2. Article first published online: 7 OCT 2009
  3. Manuscript Accepted: 13 MAR 2009
  4. Manuscript Revised: 11 MAR 2009
  5. Manuscript Received: 30 JAN 2009

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (203K)

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Neife Aparecida Guinaim Santos, Maria Augusta Carvalho Rodrigues, Nadia Maria Martins, Antonio Cardozo Santos, Cisplatin-induced nephrotoxicity and targets of nephroprotection: an update, Archives of Toxicology, 2012,

    CrossRef

  2. 2
    Etan Orgel, Shveta Jain, Lingyun Ji, Liora Pollick, Stephanie Si, Jonathan Finlay, David R. Freyer, Hearing loss among survivors of childhood brain tumors treated with an irradiation-sparing approach, Pediatric Blood & Cancer, 2012, 58, 6
    Direct Link:
  3. 3
    Rebecka L. Meyers, Daniel C. Aronson, Arthur Zimmermann, Pediatric Surgery, 2012,

    CrossRef

  4. 4
    Kay W. Chang, Clinically accurate assessment and grading of ototoxicity, The Laryngoscope, 2011, 121, 12
    Direct Link:
  5. 5
    Nedim Hadzic, Milton J. Finegold, Liver Neoplasia in Children, Clinics in Liver Disease, 2011, 15, 2, 443

    CrossRef

  6. 6
    Ponni Sivaprakasam, Abha A. Gupta, Mark L. Greenberg, Michael Capra, Paul C. Nathan, Survival and Long-term Outcomes in Children With Hepatoblastoma Treated With Continuous Infusion of Cisplatin and Doxorubicin, Journal of Pediatric Hematology/Oncology, 2011, 33, 6, e226

    CrossRef

  7. 7
    James R. Anderson, Mark Krailo, The Children's Oncology Group Routinely Applies “Lack of Efficacy” Interim Monitoring to Its Randomized Clinical Trials, The American Journal of Bioethics, 2011, 11, 3, 18

    CrossRef

  8. 8
    Current awareness: Pharmacoepidemiology and drug safety, Pharmacoepidemiology and Drug Safety, 2010, 19, 6
    Direct Link:
  9. 9
    Roderick Skinner, Nephrotoxicity of cancer treatment in children, Pediatric Health, 2010, 4, 5, 519

    CrossRef

View Full Article (HTML) Get PDF (203K)